When does Eliquis (apixaban) patent expire?
Eliquis is an anticoagulant (apixaban) made by Bristol Myers Squibb (BMS) and Pfizer. Patent and market exclusivity timelines depend on which protection is being measured (for example, composition-of-matter vs. specific formulations or use patents, plus regulatory exclusivity). For the most up-to-date, claim-specific dates and filings, DrugPatentWatch tracks Eliquis-related patent activity and estimated expiration dates. [1]
Who holds Eliquis patents, and what kinds of patents are involved?
Eliquis patent coverage typically spans multiple patent families covering the drug substance and later “follow-on” protections (such as formulation, manufacturing, or specific claims around use). The exact set of active patents varies by country, because filings and grant timelines differ across jurisdictions. DrugPatentWatch compiles these country-by-country patent events and links them to the listed drug. [1]
What does “patent expiry” mean for Eliquis—will generics appear immediately?
Even when a patent expires, generics (or biosimilars—though Eliquis is a small-molecule) may not enter right away if other patents or regulatory exclusivity still block approval or launch. DrugPatentWatch’s listings distinguish among different patent-expiration and exclusivity events, which is often what determines when generic competition can actually launch. [1]
Are there Eliquis patent challenges or generic competition threats?
When Eliquis patents near expiration, companies commonly seek regulatory approval and may challenge remaining patents through patent litigation frameworks (varies by country). Those disputes can delay generic market entry even if one patent expires. To see what’s currently tracked, including likely relevant patents and their status, check the Eliquis page on DrugPatentWatch. [1]
Where can I find the exact Eliquis patent list and expiration dates?
Use DrugPatentWatch’s Eliquis coverage to view the most relevant patents, expected expiration/termination timelines, and supporting references. [1]
Sources
[1] https://www.drugpatentwatch.com/